Pfizer Inc. (PFE) Stock Score, Valuation & Financial Research
Pfizer Inc. is in the Healthcare sector and Drug Manufacturers - General industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 28/100.
Quick answer for PFE
Pfizer Inc. currently has a Wall Street Score of 28/100. The stored market price is $27.72. Its financial score is 5/100. Its valuation score is 16/100. These figures are a research snapshot, not a buy or sell recommendation.
What Pfizer Inc. does
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar fa
PFE financial snapshot
- Wall Street Score:
- 28/100
- Current price:
- $27.72
- Market capitalization:
- $157.99B
- Revenue:
- $63.31B
- Net income:
- $7.49B
- Free cash flow:
- $9.08B
- Cash:
- $1.70B
- Total debt:
- $64.45B
- EPS:
- 1.36
- P/E ratio:
- 20.4x
- Financial score:
- 5/100
- Valuation score:
- 16/100
- Revenue score:
- 18/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $9.08B, showing positive cash generation.
- The balance sheet shows $1.70B of cash versus $64.45B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 16/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 5/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research PFE
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.